Literature DB >> 3211967

Chronic l-dopa fails to lessen rebound enhancement of self-stimulation after chronic haloperidol.

I C Rose1, M Mintz, L J Herberg.   

Abstract

Chronic treatment with haloperidol (approximately 4.8 mg/rat/day PO for 18 days) severely impaired variable-interval hypothalamic self-stimulation. Cessation of treatment was followed by a strong rebound increase in response rates at submaximal currents, to well above pretreatment rates. The rebound increase in responding was not prevented (and at submaximal currents was actually enhanced) by treatment with l-dopa plus benserazide (respectively 240 and 60 mg/kg/day PO) for 6 days after withdrawal of haloperidol. This result is at variance with previously reported findings.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3211967     DOI: 10.1016/0091-3057(88)90069-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  Effect of intracerebroventricular and systemic injections of caerulein, a CCK analogue, on electrical self-stimulation and its interaction with the CCKA receptor antagonist, L-364,718 (MK-329).

Authors:  M H Hamilton; I C Rose; L J Herberg; J S de Belleroche
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward.

Authors:  L J Herberg; I C Rose
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  The effect of a 5-HT3 receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission.

Authors:  A M Montgomery; I C Rose; L J Herberg
Journal:  J Neural Transm Gen Sect       Date:  1993

4.  5-HT1A agonists and dopamine: the effects of 8-OH-DPAT and buspirone on brain-stimulation reward.

Authors:  A M Montgomery; I C Rose; L J Herberg
Journal:  J Neural Transm Gen Sect       Date:  1991
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.